The First Case Report of Effective Treatment With Sotorasib for Metastatic Atypical Lung Carcinoid Harboring KRAS G12C Mutation and Aggressive Disseminated Lung Metastasis: A Case Report

Saiki, Masafumi; Omori, Chisa; Morikawa, Honami; Shinohara, Ken; Shimamura, So; Ohkoshi, Hiroki; Uchida, Yoshinori; Inoue, Tomohiro; Kondo, Tetsuo; Ikemura, Shinnosuke; Soejima, Kenzo

doi:10.1016/j.jtocrr.2023.100620

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the development of the KRAS G12C inhibitors sotorasib and adagrasib, few case reports have addressed the potential use of these molecules in the setting of NENs harboring KRAS G12C mutations. One case, showing some clinical benefit of sotorasib in a patient with KRAS G12C mutant atypical lung carcinoid, has been recently reported [ 126 , 127 ]. More data are required to address the impact of KRAS inhibitors in the setting of NENs, and patients whose tumors harbor KRAS -actionable mutations should be referred for enrollment in clinical trials.…”

Section: Unraveling Molecular Characterization Of Upo-nens: Time For ...mentioning

confidence: 99%

Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives

Corti,

Rossi,

Cafaro

et al. 2024

Cancers

View full text Add to dashboard Cite

Among neuroendocrine neoplasms (NENs), a non-negligible proportion (9–22%) is represented by sufferers of NENs of unknown primary origin (UPO), a poor prognostic group with largely unmet clinical needs. In the absence of standard therapeutic algorithms, current guidelines suggest that the treatment of UPO-NENs should be based on tumor clinical-pathological characteristics, disease burden, and patient conditions. Chemotherapy represents the backbone for the treatment of high-grade poorly differentiated UPO-NENs, usually providing deep but short-lasting responses. Conversely, the spectrum of available systemic therapy options for well-differentiated UPO-NENs may range from somatostatin analogs in indolent low-grade tumors, to peptide receptor radioligand therapy, tyrosine kinase inhibitors (TKIs), or chemotherapy for more aggressive tumors or in case of high disease burden. In recent years, molecular profiling has provided deep insights into the molecular landscape of UPO-NENs, with both diagnostic and therapeutic implications. Although preliminary, interesting activity data have been provided about upfront chemoimmunotherapy, the use of immune checkpoint inhibitors (ICIs), and the combination of ICIs plus TKIs in this setting. Here, we review the literature from the last 30 years to examine the available evidence about the treatment of UPO-NENs, with a particular focus on future perspectives, including the expanding scenario of targeted agents in this setting.

show abstract

Section: Unraveling Molecular Characterization Of Upo-nens: Time For ...mentioning

confidence: 99%

Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives

Corti,

Rossi,

Cafaro

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

The First Case Report of Effective Treatment With Sotorasib for Metastatic Atypical Lung Carcinoid Harboring KRAS G12C Mutation and Aggressive Disseminated Lung Metastasis: A Case Report

Cited by 1 publication

References 6 publications

Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives

Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives

Contact Info

Product

Resources

About